# The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population

> **NCT03057457** · — · UNKNOWN · sponsor: **BioPorto Diagnostics** · enrollment: 530 (estimated)

## Conditions studied

- Kidney Injury

## Interventions

- **DEVICE:** NGAL Test

## Key facts

- **NCT ID:** NCT03057457
- **Lead sponsor:** BioPorto Diagnostics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03
- **Primary completion:** 2017-12
- **Final completion:** 2018-02
- **Target enrollment:** 530 (ESTIMATED)
- **Last updated:** 2017-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03057457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03057457, "The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03057457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*